Brian Barash, MD
Psychiatry · Kansas City, MONPI 1689663049
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $734,928 of the $856,307 with a category attached, or 85.8%. 29 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 24.8% of the total. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,559 payments — averaging $549.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$212K
- AbbVie$182K
- Supernus Pharmaceuticals, Inc.$123K
- Otsuka America Pharmaceutical, Inc.$109K
- Alkermes, Inc.$96K
- Axsome Therapeutics, Inc.$40K
- plus $96K from 23 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$500
What the payments were for
- Consulting fees$34,4854%
- Speaking & faculty fees$734,92886%
- Travel & lodging$61,0767%
- Food & beverage$25,7693%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 240 | $211,985 |
| AbbVie(2 entities) | 408 | $181,723 |
| Supernus Pharmaceuticals, Inc. | 220 | $122,768 |
| Otsuka America Pharmaceutical, Inc. | 166 | $108,548 |
| Alkermes, Inc. | 116 | $96,147 |
| Axsome Therapeutics, Inc. | 38 | $39,525 |
| Tris Pharma Inc | 101 | $35,157 |
| Corium, LLC | 42 | $27,753 |
| Eisai Inc. | 32 | $15,665 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $14,580 |
| Sunovion Pharmaceuticals Inc. | 44 | $612 |
| Johnson & Johnson | 24 | $395 |
| Neos Therapeutics, LP | 19 | $280 |
| Vanda Pharmaceuticals Inc. | 16 | $207 |
| Lundbeck LLC | 19 | $203 |
| Shire North American Group Inc | 11 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $128 |
| Jazz Pharmaceuticals Inc. | 6 | $99 |
| Ironshore Pharmaceuticals Inc. | 5 | $88 |
| Vertical Pharmaceuticals, LLC | 5 | $72 |
| Brainsway USA Inc | 1 | $71 |
| Neuronetics, Inc. | 1 | $49 |
| Almatica Pharma LLC | 2 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$201,108
- VRAYLAR$177,549
- ARISTADA$175,370
- QELBREE$112,977
- Austedo XR$96,876
- REXULTI$73,748
- UZEDY$56,170
- AUSTEDO$55,791
- ARISTADA INITIO$43,610
- Auvelity$38,724
- Dyanavel XR$33,693
- ABILIFY MAINTENA$32,881
- Quillichew ER$31,569
- Quillivant$30,269
- Azstarys$27,298
- Dayvigo$15,650
- CAPLYTA$14,032
- ABILIFY ASIMTUFII$8,119
- Quillivant XR$1,300
- VIIBRYD$200
How this compares
$856,307 in reported general payments places this provider in the 95th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 12 | $143,686 |
| RexultiBrexpiprazole | 19 | $30,557 |
| VraylarCariprazine Hcl | 19 | $29,414 |
| VyvanseLisdexamfetamine Dimesylate | 37 | $14,348 |
| Lisdexamfetamine Dimesylate | 43 | $11,406 |
| Dyanavel XrAmphetamine | 12 | $5,502 |
| Duloxetine Hcl | 190 | $4,393 |
| Bupropion XlBupropion Hcl | 168 | $3,798 |
| Oxcarbazepine | 44 | $3,312 |
| Ziprasidone Hcl | 53 | $3,244 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 68 | $3,018 |
| Olanzapine | 26 | $2,145 |
| Paliperidone ErPaliperidone | 16 | $2,088 |
| Divalproex Sodium ErDivalproex Sodium | 39 | $2,030 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 45 | $2,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $211,985 | $143,68612 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $108,548 | $30,55719 claims |
| AbbVieVraylar | $181,723 | $29,41419 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $128 | $14,34837 claims |
| Tris Pharma IncDyanavel Xr | $35,157 | $5,50212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Kansas City
- Mark CannonKansas City$19K
- Syed KarimKansas City$17K
- Asim UlusaracKansas City$12K
- Christine TruebloodKansas City$12K
- Kevin KennettKansas City$12K
- Gregory MattingleySaint Charles$4.7M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- Casey ProughLees Summit$615K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.